Autosomal recessive distal spinal muscular atrophy 2
disease diseaseOn this page
Also known as autosomal recessive distal spinal muscular atrophy type 2dHMNJDSMA2hereditary motor neuropathy, Jerash typeHMNJMNDJmotor neuropathy, distal, Jerash typeneuropathy, distal hereditary motor, Jerash typespinal muscular atrophy, distal, autosomal recessive, 2spinal muscular atrophy, distal, autosomal recessive, type 2
Summary
Autosomal recessive distal spinal muscular atrophy 2 (MONDO:0011585) is a disease caused by SIGMAR1 (GenCC Strong), with 4 cohort genes.
At a glance
- Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
- Causal gene: SIGMAR1 (GenCC Strong)
- Cohort genes: 4
- ClinVar variants: 184
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Cases/families | 30 | Worldwide | Validated | |
| Point prevalence | <1 / 1 000 000 | Worldwide | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | autosomal recessive distal spinal muscular atrophy 2 |
| Mondo ID | MONDO:0011585 |
| MeSH | C535715 |
| OMIM | 605726 |
| Orphanet | 139552 |
| DOID | DOID:0111065 |
| SNOMED CT | 763533003 |
| UMLS | C1854023 |
| MedGen | 344189 |
| GARD | 0010133 |
| Is cancer (heuristic) | no |
Also known as: autosomal recessive distal spinal muscular atrophy type 2 · dHMNJ · DSMA2 · hereditary motor neuropathy, Jerash type · HMNJ · MNDJ · motor neuropathy, distal, Jerash type · neuropathy, distal hereditary motor, Jerash type · spinal muscular atrophy, distal, autosomal recessive, 2 · spinal muscular atrophy, distal, autosomal recessive, type 2
Data availability: 184 ClinVar variants · 2 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › spinal cord disorder › anterior horn disorder › spinal muscular atrophy › autosomal recessive distal spinal muscular atrophy 2
Related subtypes (18): spinal muscular atrophy-progressive myoclonic epilepsy syndrome, scapuloperoneal spinal muscular atrophy, autosomal dominant, spinal muscular atrophy, facioscapulohumeral type, adult-onset proximal spinal muscular atrophy, autosomal dominant, spinal muscular atrophy, segmental, spinal muscular atrophy, Ryukyuan type, scapuloperoneal spinal muscular atrophy, autosomal recessive, X-linked distal spinal muscular atrophy type 3, infantile-onset X-linked spinal muscular atrophy, autosomal recessive distal spinal muscular atrophy 1, neuronopathy, distal hereditary motor, autosomal recessive 3, neuronopathy, distal hereditary motor, autosomal recessive 4, neuronopathy, distal hereditary motor, autosomal recessive 5, neuronopathy, distal hereditary motor, autosomal dominant, bulbospinal muscular atrophy, spinal muscular atrophy with respiratory distress type 2, proximal spinal muscular atrophy, spinal muscular atrophy type 0
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
184 retrieved; paginated sample, class counts are floors:
77 likely benign, 70 uncertain significance, 16 pathogenic, 8 benign, 6 likely pathogenic, 3 conflicting classifications of pathogenicity, 2 benign/likely benign, 2 pathogenic/likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 183041 | NM_006736.6(DNAJB2):c.229+1G>A | DNAJB2 | Pathogenic | criteria provided, single submitter |
| 217886 | NM_006736.6(DNAJB2):c.352+1G>A | DNAJB2 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1454893 | NM_005866.4(SIGMAR1):c.86G>A (p.Trp29Ter) | LOC130001681 | Pathogenic | criteria provided, single submitter |
| 208123 | NM_005866.4(SIGMAR1):c.151+1G>T | LOC130001681 | Pathogenic | no assertion criteria provided |
| 2083521 | NM_005866.4(SIGMAR1):c.125_126del (p.Ile42fs) | LOC130001681 | Pathogenic | criteria provided, single submitter |
| 569448 | NM_005866.4(SIGMAR1):c.13del (p.Val5fs) | LOC130001681 | Pathogenic | criteria provided, single submitter |
| 985499 | NM_005866.4(SIGMAR1):c.14_20dup (p.Arg8fs) | LOC130001681 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1067324 | NM_005866.4(SIGMAR1):c.492G>A (p.Trp164Ter) | SIGMAR1 | Pathogenic | criteria provided, single submitter |
| 209190 | NM_005866.4(SIGMAR1):c.283dup (p.Leu95fs) | SIGMAR1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 2938415 | NM_005866.4(SIGMAR1):c.456_471del (p.Val153fs) | SIGMAR1 | Pathogenic | criteria provided, single submitter |
| 2945263 | NM_005866.4(SIGMAR1):c.374C>A (p.Ser125Ter) | SIGMAR1 | Pathogenic | criteria provided, single submitter |
| 30238 | NM_005866.4(SIGMAR1):c.304G>C (p.Glu102Gln) | SIGMAR1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 3748188 | NM_005866.4(SIGMAR1):c.403C>T (p.Gln135Ter) | SIGMAR1 | Pathogenic | criteria provided, single submitter |
| 3749597 | NM_005866.4(SIGMAR1):c.217_220del (p.Val73fs) | SIGMAR1 | Pathogenic | criteria provided, single submitter |
| 3756143 | NM_005866.4(SIGMAR1):c.445+1G>A | SIGMAR1 | Pathogenic | criteria provided, single submitter |
| 575556 | NM_005866.4(SIGMAR1):c.194T>A (p.Leu65Gln) | SIGMAR1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 623389 | NM_005866.4(SIGMAR1):c.238C>T (p.Gln80Ter) | SIGMAR1 | Pathogenic | criteria provided, single submitter |
| 650504 | NM_005866.4(SIGMAR1):c.19del (p.Arg7fs) | SIGMAR1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 183042 | NM_006736.6(DNAJB2):c.14A>G (p.Tyr5Cys) | DNAJB2 | Likely pathogenic | criteria provided, single submitter |
| 1067640 | NM_005866.4(SIGMAR1):c.152-2A>T | SIGMAR1 | Likely pathogenic | criteria provided, single submitter |
| 1285377 | NM_005866.4(SIGMAR1):c.109_110del (p.Phe37fs) | SIGMAR1 | Likely pathogenic | criteria provided, single submitter |
| 431075 | NM_005866.4(SIGMAR1):c.561_576del (p.Asp188fs) | SIGMAR1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4356097 | NM_005866.4(SIGMAR1):c.353-2A>G | SIGMAR1 | Likely pathogenic | criteria provided, single submitter |
| 873316 | NM_005866.4(SIGMAR1):c.448G>A (p.Glu150Lys) | SIGMAR1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2196903 | NM_005866.4(SIGMAR1):c.356G>A (p.Arg119His) | SIGMAR1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 465869 | NM_005866.4(SIGMAR1):c.463G>A (p.Gly155Arg) | SIGMAR1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 573115 | NM_005866.4(SIGMAR1):c.632G>A (p.Arg211Gln) | SIGMAR1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 584345 | NC_000009.11:g.(?34458984)(36277059_?)dup | CREB3 | Uncertain significance | criteria provided, single submitter |
| 1001150 | NM_005866.4(SIGMAR1):c.61G>A (p.Val21Met) | LOC130001681 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1025205 | NM_005866.4(SIGMAR1):c.89T>C (p.Leu30Pro) | LOC130001681 | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 6 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| SIGMAR1 | Strong | Autosomal recessive | autosomal recessive distal spinal muscular atrophy 2 | 6 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| SIGMAR1 | Orphanet:139552 | Distal hereditary motor neuropathy, Jerash type |
| SIGMAR1 | Orphanet:300605 | Juvenile amyotrophic lateral sclerosis |
| DNAJB2 | Orphanet:314485 | Young adult-onset distal hereditary motor neuropathy |
| DNAJB2 | Orphanet:443950 | DNAJB2-related Charcot-Marie-Tooth disease type 2 |
Cohort genes → proteins
4 cohort genes, 4 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 4 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| SIGMAR1 | HGNC:8157 | ENSG00000147955 | Q99720 | Sigma non-opioid intracellular receptor 1 | gencc,clinvar |
| CREB3 | HGNC:2347 | ENSG00000107175 | O43889 | Cyclic AMP-responsive element-binding protein 3 | clinvar |
| SPATA31G1 | HGNC:31418 | ENSG00000174038 | Q5VYM1 | Spermatogenesis-associated protein 31G1 | clinvar |
| DNAJB2 | HGNC:5228 | ENSG00000135924 | P25686 | DnaJ homolog subfamily B member 2 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. |
| CREB3 | Cyclic AMP-responsive element-binding protein 3 | Endoplasmic reticulum (ER)-bound sequence-specific transcription factor that directly binds DNA and activates transcription. |
| SPATA31G1 | Spermatogenesis-associated protein 31G1 | Dispensable for normal development and fertility. |
| DNAJB2 | DnaJ homolog subfamily B member 2 | Functions as a co-chaperone, regulating the substrate binding and activating the ATPase activity of chaperones of the HSP70/heat shock protein 70 family. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 4 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 4 | 1.8× | 0.097 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| SIGMAR1 | Other/Unknown | no | ERG2_sigma1_rcpt-like | |
| CREB3 | Other/Unknown | no | bZIP, bZIP_sf, CREB_ATF_subfamily | |
| SPATA31G1 | Other/Unknown | no | Spata31g1-like | |
| DNAJB2 | Other/Unknown | no | DnaJ_domain, UIM_dom, DnaJ_domain_CS |
Expression context
Cohort genes with no expression data: 0.
3 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 4 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| liver | 1 |
| right lobe of liver | 1 |
| stromal cell of endometrium | 1 |
| adenohypophysis | 1 |
| popliteal artery | 1 |
| right testis | 1 |
| cardiac muscle of right atrium | 1 |
| kidney epithelium | 1 |
| left ventricle myocardium | 1 |
| C1 segment of cervical spinal cord | 1 |
| cerebellar hemisphere | 1 |
| right hemisphere of cerebellum | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| SIGMAR1 | 282 | ubiquitous | marker | right lobe of liver, stromal cell of endometrium, liver |
| CREB3 | 276 | ubiquitous | marker | adenohypophysis, popliteal artery, right testis |
| SPATA31G1 | 153 | tissue_specific | yes | kidney epithelium, cardiac muscle of right atrium, left ventricle myocardium |
| DNAJB2 | 281 | ubiquitous | marker | C1 segment of cervical spinal cord, right hemisphere of cerebellum, cerebellar hemisphere |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| DNAJB2 | 2,884 |
| SIGMAR1 | 1,993 |
| CREB3 | 1,969 |
| SPATA31G1 | 811 |
Structural data
PDB: 2 · AlphaFold-only: 2 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| SIGMAR1 | Q99720 | 5 |
| DNAJB2 | P25686 | 1 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| CREB3 | O43889 | 61.35 |
| SPATA31G1 | Q5VYM1 | 39.71 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 4 evidence-associated genes (2 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| CREB3 factors activate genes | 1 | 634.4× | 0.009 | CREB3 |
| Potential therapeutics for SARS | 1 | 57.1× | 0.052 | SIGMAR1 |
| SARS-CoV Infections | 1 | 27.7× | 0.072 | SIGMAR1 |
| Viral Infection Pathways | 1 | 15.4× | 0.095 | SIGMAR1 |
| Infectious disease | 1 | 12.4× | 0.095 | SIGMAR1 |
| Disease | 1 | 6.5× | 0.147 | SIGMAR1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| positive regulation of deacetylase activity | 1 | 5617.3× | 0.004 | CREB3 |
| regulation of protein folding | 1 | 5617.3× | 0.004 | DNAJB2 |
| negative regulation of protein deubiquitination | 1 | 2808.7× | 0.005 | DNAJB2 |
| release from viral latency | 1 | 1872.4× | 0.005 | CREB3 |
| negative regulation of inclusion body assembly | 1 | 561.7× | 0.012 | DNAJB2 |
| response to alcohol | 1 | 510.7× | 0.012 | SIGMAR1 |
| positive regulation of ATP-dependent activity | 1 | 468.1× | 0.012 | DNAJB2 |
| induction of positive chemotaxis | 1 | 330.4× | 0.012 | CREB3 |
| protein homotrimerization | 1 | 330.4× | 0.012 | SIGMAR1 |
| regulation of protein ubiquitination | 1 | 295.6× | 0.012 | DNAJB2 |
| negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1 | 280.9× | 0.012 | CREB3 |
| positive regulation of monocyte chemotaxis | 1 | 267.5× | 0.012 | CREB3 |
| regulation of neuron apoptotic process | 1 | 234.1× | 0.012 | SIGMAR1 |
| integrated stress response signaling | 1 | 234.1× | 0.012 | CREB3 |
| negative regulation of protein binding | 1 | 208.1× | 0.012 | DNAJB2 |
| protein refolding | 1 | 208.1× | 0.012 | DNAJB2 |
| positive regulation of calcium ion transport | 1 | 193.7× | 0.012 | CREB3 |
| neuron cellular homeostasis | 1 | 151.8× | 0.015 | DNAJB2 |
| regulation of postsynapse assembly | 1 | 114.6× | 0.019 | SIGMAR1 |
| response to unfolded protein | 1 | 100.3× | 0.019 | DNAJB2 |
| endoplasmic reticulum unfolded protein response | 1 | 98.5× | 0.019 | CREB3 |
| negative regulation of cell cycle | 1 | 96.8× | 0.019 | CREB3 |
| lipid transport | 1 | 87.8× | 0.020 | SIGMAR1 |
| DNA-templated transcription | 1 | 74.9× | 0.021 | CREB3 |
| regulation of cell growth | 1 | 73.9× | 0.021 | CREB3 |
| positive regulation of protein ubiquitination | 1 | 71.1× | 0.021 | DNAJB2 |
| positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1 | 70.2× | 0.021 | DNAJB2 |
| regulation of protein localization | 1 | 68.5× | 0.021 | DNAJB2 |
| ERAD pathway | 1 | 60.4× | 0.023 | DNAJB2 |
| negative regulation of cell growth | 1 | 48.0× | 0.028 | DNAJB2 |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 3
Druggability breadth: 1 of 4 evidence-associated genes (25%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| SIGMAR1 | PENTAZOCINE |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| SIGMAR1 | 148 | 4 |
| CREB3 | 0 | 0 |
| SPATA31G1 | 0 | 0 |
| DNAJB2 | 0 | 0 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| PENTAZOCINE | 4 | SIGMAR1 |
| PROGESTERONE | 4 | SIGMAR1 |
| METHYSERGIDE | 4 | SIGMAR1 |
| DICYCLOMINE | 4 | SIGMAR1 |
| PROPARACAINE | 4 | SIGMAR1 |
| PRAMOXINE | 4 | SIGMAR1 |
| DIMENHYDRINATE | 4 | SIGMAR1 |
| DIHYDROERGOTAMINE MESYLATE | 4 | SIGMAR1 |
| CINACALCET HYDROCHLORIDE | 4 | SIGMAR1 |
| AZELASTINE HYDROCHLORIDE | 4 | SIGMAR1 |
| METHAMPHETAMINE | 4 | SIGMAR1 |
| BENZTROPINE | 4 | SIGMAR1 |
| LEVOBUNOLOL | 4 | SIGMAR1 |
| DEXCHLORPHENIRAMINE | 4 | SIGMAR1 |
| RAMELTEON | 4 | SIGMAR1 |
| OXYBUTYNIN | 4 | SIGMAR1 |
| MIFEPRISTONE | 4 | SIGMAR1 |
| ILOPERIDONE | 4 | SIGMAR1 |
| TRIHEXYPHENIDYL | 4 | SIGMAR1 |
| TRIFLUPERIDOL | 4 | SIGMAR1 |
| TEGASEROD MALEATE | 4 | SIGMAR1 |
| HYDROXYCHLOROQUINE | 4 | SIGMAR1 |
| PRAZOSIN HYDROCHLORIDE | 4 | SIGMAR1 |
| VILAZODONE HYDROCHLORIDE | 4 | SIGMAR1 |
| CLEMASTINE | 4 | SIGMAR1 |
| DOXEPIN | 4 | SIGMAR1 |
| PROPRANOLOL HYDROCHLORIDE | 4 | SIGMAR1 |
| BETAXOLOL HYDROCHLORIDE | 4 | SIGMAR1 |
| LOPERAMIDE HYDROCHLORIDE | 4 | SIGMAR1 |
| TERCONAZOLE | 4 | SIGMAR1 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| SIGMAR1 | 619 | Binding:610, Functional:5, ADMET:3, Unclassified:1 |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| SIGMAR1 | 619 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| PENTAZOCINE | 4 | SIGMAR1 |
| PROGESTERONE | 4 | SIGMAR1 |
| METHYSERGIDE | 4 | SIGMAR1 |
| DICYCLOMINE | 4 | SIGMAR1 |
| PROPARACAINE | 4 | SIGMAR1 |
| PRAMOXINE | 4 | SIGMAR1 |
| DIMENHYDRINATE | 4 | SIGMAR1 |
| DIHYDROERGOTAMINE MESYLATE | 4 | SIGMAR1 |
| CINACALCET HYDROCHLORIDE | 4 | SIGMAR1 |
| AZELASTINE HYDROCHLORIDE | 4 | SIGMAR1 |
| METHAMPHETAMINE | 4 | SIGMAR1 |
| BENZTROPINE | 4 | SIGMAR1 |
| LEVOBUNOLOL | 4 | SIGMAR1 |
| DEXCHLORPHENIRAMINE | 4 | SIGMAR1 |
| RAMELTEON | 4 | SIGMAR1 |
| OXYBUTYNIN | 4 | SIGMAR1 |
| MIFEPRISTONE | 4 | SIGMAR1 |
| ILOPERIDONE | 4 | SIGMAR1 |
| TRIHEXYPHENIDYL | 4 | SIGMAR1 |
| TRIFLUPERIDOL | 4 | SIGMAR1 |
| TEGASEROD MALEATE | 4 | SIGMAR1 |
| HYDROXYCHLOROQUINE | 4 | SIGMAR1 |
| PRAZOSIN HYDROCHLORIDE | 4 | SIGMAR1 |
| VILAZODONE HYDROCHLORIDE | 4 | SIGMAR1 |
| CLEMASTINE | 4 | SIGMAR1 |
| DOXEPIN | 4 | SIGMAR1 |
| PROPRANOLOL HYDROCHLORIDE | 4 | SIGMAR1 |
| BETAXOLOL HYDROCHLORIDE | 4 | SIGMAR1 |
| LOPERAMIDE HYDROCHLORIDE | 4 | SIGMAR1 |
| TERCONAZOLE | 4 | SIGMAR1 |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | SIGMAR1 |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 3 | CREB3, SPATA31G1, DNAJB2 |
Undrugged target profiles
3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| CREB3 | 0 | — |
| SPATA31G1 | 0 | — |
| DNAJB2 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.